BPC 157: What It Is, What We Know, and Why Its Use for Arthritis Remains Unproven San Diego Orthobiologics Medical Group FDA Peptide Reclassification 2026: What It Means for Providers FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of Pharmacy Purchasing & Products Magazine Peptide Therapy in Austin, TX Austin Plastic Surgeon Dr. Chuma FDA's Bulks List: Section 503A